Phaarmasia Ltd. (BSE: 523620) is a Hyderabad, Telangana-based company in the Pharmaceuticals industry. With a market capitalisation of ₹55 Cr, it ranks #3,780 by market cap among the 6,137 Indian listed companies on FinBizNet, and #50 of 63 in Pharmaceuticals. At ₹91.29 (as of 25 Oct 2026), the share price is 30.7% below its 52-week high of ₹131.75 and 179.2% above its 52-week low of ₹32.70. The share price is up 179.2% over one year and up 2.1% over three months.
| Current Price | ₹91.29 |
|---|---|
| Market Cap | ₹55 Cr |
| BSE Code | 523620 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Pharmaceuticals |
| P/E Ratio | 3.1 |
| Return on Equity | 113.99% |
| Return on Assets | 5.57% |
| 52-Week Range | ₹32.70 – ₹131.75 |
| 1-Year Price Change | +179.2% |
| 3-Month Price Change | +2.1% |
| Beta (1Y) | 0.49 |
| Headquarters | Hyderabad, Telangana |
| Website | www.phaarmasia.in |
Phaarmasia Limited manufactures and sells oral contraceptive pills and iron tablets in India. It offers hormone products, including mifepristone and misoprostaol, desogestrel and ethinyl estradiol, estradiol valerate, levonorgestrel and ethinyl estradiol, medroxyprogesterone acetate, cabergoline, clomiphene citrate, levonorgestrel, progesterone, fluoxymesterone, liothyronine sodium, chlorodehydromethyltestosterone, liothyronine sodium, oxandrolone tablets, testosterone cypionate, methenolone enanthate, drostanolone, testosterone, trenbolone, and stanozolol cypionate injections. The company provides herbal products, such as herbal toothpaste, cough and sore throat reliver, and mouth ulcer gel under the Smyle brand name. Phaarmasia Limited was incorporated in 1981 and is based in Hyderabad, India.
1. Pharmaceuticals-This segment engages in the manufacture and sale of pharmaceutical products primarily cosmetics and oral contraceptive pills.
1. Pharmaceuticals-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Abbott India Ltd. | ₹55,577 Cr | 35.5 | 34.46% | ₹1,814 Cr | -16.1% |
| Ajanta Pharma Limited | ₹41,591 Cr | 39 | 25.39% | ₹1,626 Cr | +36.3% |
| Emcure Pharmaceuticals Ltd | ₹34,533 Cr | 36.3 | 19.57% | ₹2,580 Cr | +31.1% |
| Piramal Pharma Ltd | ₹26,284 Cr | -79 | -4.00% | ₹2,270 Cr | -1.6% |
| RUBICON RESEARCH LIMITED | ₹24,972 Cr | 97.6 | 19.14% | ₹534 Cr | — |
| Caplin Point Laboratories Ltdte | ₹17,484 Cr | 26.9 | 19.94% | ₹610 Cr | +10.3% |
| Pfizer Ltd. | ₹17,448 Cr | 24.1 | 17.16% | ₹653 Cr | -32.1% |
| Eris Lifesciences Ltd | ₹15,877 Cr | 24.8 | 18.07% | ₹873 Cr | -30.8% |
| Phaarmasia Ltd. | ₹55 Cr | 3.1 | 113.99% | — | +179.2% |
Listed by market capitalisation. Ratios are shown for context only.
Phaarmasia Ltd. is trading at ₹91.29, with a market capitalisation of ₹55 Cr.
Phaarmasia Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Pharmaceuticals).
Phaarmasia Ltd. has a P/E of 3.1 and a return on equity of 113.99%.
Phaarmasia Ltd. is listed on the BSE under the scrip code 523620.
Phaarmasia Ltd.'s share price is up 179.2% over one year and up 2.1% over three months. Its 52-week range is ₹32.70 to ₹131.75.
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.